CABALETTA BIO INC. -

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

02 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

22 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Jefferies Healthcare Conference

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

22 May 2023 15:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

17 May 2023 21:16:01 By Nasdaq GlobeNewswire

Cabaletta Bio Announces Proposed Public Offering of Common Stock

17 May 2023 15:01:00 By Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

16 May 2023 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

11 May 2023 06:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

02 May 2023 15:35:00 By Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

01 May 2023 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

13 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

31 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

16 Mar 2023 06:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

28 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

05 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Cabaletta Bio Announces $35 Million Offering

08 Dec 2022 06:00:00 By Nasdaq GlobeNewswire